Evidence map›Paper›PMID 26259542›Full record

Trial reportVaccine2015

Delayed BCG vaccination results in minimal alterations in T cell immunogenicity of acellular pertussis and tetanus immunizations in HIV-exposed infants.

Anna K Blakney, Christophe Toukam Tchakoute, Anneke C Hesseling, Elvis B Kidzeru, Christine E Jones, Jo-Ann S Passmore, Donald L Sodora, Clive M Gray, Heather B Jaspan

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02062580 (Influence of BCG Immunization on Immune Responses and Disease Progression in South African HIV Exposed and Infected Infants), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02062580 phase2completednot on this map

Influence of BCG Immunization on Immune Responses and Disease Progression in South African HIV Exposed and Infected Infants

TypeinterventionalSponsorUniversity of Cape TownRan2010Enrolled149ConditionsHIV Exposure, HIV InfectionArmsBCG
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Variances in BCG protection against COVID-19 mortality: A global assessment.Journal of clinical tuberculosis and other mycobacterial diseases · 2021
    Article
  5. Article
  6. Review
  7. Article
  8. Current status of new tuberculosis vaccine in children.Human vaccines & immunotherapeutics · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Anna K BlakneyDepartment of Bioengineering, University of Washington, United States; Division of Immunology, Institute of Infectious Disease and Molecular Medicine and Clinical Laboratory Sciences, University of Cape Town, South Africa.
Christophe Toukam TchakouteDivision of Immunology, Institute of Infectious Disease and Molecular Medicine and Clinical Laboratory Sciences, University of Cape Town, South Africa.
Anneke C HesselingDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Elvis B KidzeruDivision of Immunology, Institute of Infectious Disease and Molecular Medicine and Clinical Laboratory Sciences, University of Cape Town, South Africa.
Christine E JonesDivision of Immunology, Institute of Infectious Disease and Molecular Medicine and Clinical Laboratory Sciences, University of Cape Town, South Africa; Paediatric Infectious Diseases Research Group, St George's, University of London, UK.
Jo-Ann S PassmoreDivision of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town and National Health Laboratory Services, South Africa.
Donald L SodoraCenter for Infectious Disease Research (Formerly Seattle Biomed), Seattle, WA, United States.
Clive M GrayDivision of Immunology, Institute of Infectious Disease and Molecular Medicine and Clinical Laboratory Sciences, University of Cape Town, South Africa; National Health Laboratory Services, Groote Schuur Hospital, Cape Town, South Africa.
Heather B JaspanDivision of Immunology, Institute of Infectious Disease and Molecular Medicine and Clinical Laboratory Sciences, University of Cape Town, South Africa; Seattle Children's Research Institute and Departments of Pediatrics and Global Health, University of WA, Seattle, WA, United States. Electronic address: hbjaspan@gmail.com.
University of Cape Town · ZANational Health Laboratory Service · ZACenter for Infectious Disease Research · USDesmond Tutu HIV Foundation · ZAInfectious Disease Research Institute · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Risk of Neonatal Vaccination for HIV/SIV Exposed InfantsR01DE023047 · NIDCR · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI SODORA, DONALD L · 2013 to 2016
$3.5M
Assessing feeding practices, immune activation, and HIV risk in African infantsK08HD069201 · NICHD · SEATTLE CHILDREN'S HOSPITAL · PI JASPAN, HEATHER BERYL · 2011 to 2015
$644k
NICHD NIH HHS HD-069201NICHD NIH HHS K08 HD069201NIDCR NIH HHS DE023047NIDCR NIH HHS R01 DE023047NIH HHS P51 OD010425
6 · The paper itself

Abstract

backgroundBacille Calmette-Guerin (BCG) is effective in preventing disseminated tuberculosis (TB) in children but may also have non-specific benefits, and is thought to improve immunity to unrelated antigens through trained innate immunity. In HIV-infected infants, there is a risk of BCG-associated adverse events. We aimed to explore whether delaying BCG vaccination by 8 weeks, in utero or perinatal HIV infection is excluded, affected T-cell responses to B. pertussis (BP) and tetanus toxoid (TT), in HIV-exposed, uninfected infants.

methodsInfants were randomized to receive BCG vaccination at birth or 8 weeks of age. At 8 and 14 weeks, T cell proliferation and intracellular cytokine (IL-2, IL-13, IL-17, and IFN-γ) expression was analyzed in response to BP, TT and Staphylococcal enterotoxin B (SEB) antigens.

resultsDelaying BCG vaccination did not alter T-cell proliferation to BP or TT antigens. Infants immunized with BCG at birth had higher CD4+ T cell proliferation to SEB at 14 weeks of age (p=0.018). Birth-vaccinated infants had increased CD8+ IL-2 expression in response to BP, but not TT or SEB, at 8 weeks. Infants vaccinated with BCG at 8 weeks had significantly lower IL-13 expression by BP-specific CD4+ and CD8+ T cells at 14 weeks (p=0.032 and p=0.0035, respectively). There were no observed differences in multifunctional cytokine response to TT, BP or SEB between infants vaccinated with BCG at birth versus 8 weeks of age.

conclusionDelaying BCG vaccination until 8 weeks of age results in robust T-cellular responses to BP and TT in HIV-exposed infants. CLINICAL TRIAL REGISTRY: NCT02062580.

Indexed as

Environmental ExposureHIV InfectionsImmunization ScheduleBCG VaccineCell ProliferationCytokinesFemaleHumansInfantMalePertussis VaccineTetanus ToxoidTime FactorsT-LymphocytesBCG VaccineCytokinesPertussis VaccineTetanus ToxoidBCG vaccineHIVInfantsPertussisT cellTetanus

Identifiers

PMID26259542
PMCPMC4562895
OpenAlexW1066527732

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.